Vermillion secures $17.6M to expand its push for ovarian cancer Dx

Vermillion ($VRML) pulled in $17.6 million through the sale of warrants, completing a $31 million equity financing first disclosed in May. The Austin, TX, diagnostics outfit said that Oracle Investment Management, Jack Schuler, Matthew Strobeck and other investors exercised their warrants in the transaction, purchasing 12.1 million shares of common stock at $1.46 per share. The funding will help the company boost sales and reimbursement efforts for Ova1, its pre-surgery algorithmic blood test designed to screen for ovarian cancer. Item

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.